RetaMaps

Little Elm Medical Clinic

Little Elm Medical Clinic · 730 East Eldorado Parkway · Little Elm, TX 75068

4.6· 227 Google reviews

Listing updated October 2, 2026

Retatrutide outlook for this practice

No current plans confirmed — RetaMaps has not yet confirmed this practice's intentions regarding retatrutide. Inclusion on RetaMaps does not mean the provider offers or will offer retatrutide.

Care described on the practice's website

  • Medically supervised weight loss

About this practice

Little Elm Medical Clinic is an internal medicine and primary care practice in Little Elm, Texas. Its website describes same-day visits, chronic care and preventive services, on-site lab testing through a partner laboratory, and virtual visits for existing patients. Clinicians named on the site include John G. Flores, MD, Jill E. Wolf, MD, and Kimberly S. Wolf, APRN, FNP-C. On Google it has a 4.6-star rating across 227 reviews dating back to 2022, with 40 in the past year, and reviewers most often mention the staff and feeling cared for. The site doesn't name specific GLP-1 medications, so ask which weight-management options it currently offers.

Services & access

Advertises semaglutide todayNot listed
Advertises tirzepatide todayNot listed
Telehealth visitsYes
Cash pay accepted—
Accepts insurance — per practice websiteYes
Accepting new patients — per practice websiteYes

"Not listed" means we didn't find this stated on the practice's public pages — it doesn't mean no. — means unknown. Medication rows describe currently FDA-approved GLP-1 medications the practice advertises today, not retatrutide. Confirm details directly with the practice.

Review activity

★ 4.6
Google rating · 227 reviews
40
reviews in the past year (avg ★ 4.9)
1
reviews mention weight loss

Counts computed by RetaMaps from public Google reviews; most recent review 2026-09-01. Read the reviews themselves on the practice's Google listing.

What patients say

Rated ★4.6 across 227 Google reviews. Of the 100 reviews we analyzed, 95 (95%) are positive (4–5★) and 5 (5%) are negative (1–2★).

What patients like

  • Friendly, helpful staff41 reviews
  • Feeling listened to22 reviews
  • Knowledgeable, professional providers12 reviews
  • Easy scheduling and communication10 reviews

Common complaints

  • Staff or front-desk issues3 of 5 negative
5★
94
4★
1
3★
0
2★
0
1★
5

Most recent Google reviews

Shiloh V.★★★★★2026-07-09

Scheduling was quick and efficient. Staff was friendly and attentive. Dr. Wolfe took extraordinary care to listen and comprehend my entire back story leading to current day, ensuring a proper plan for medical care. Much appreciated and looking forward to future care as needed.

Christina B.★★★★★2026-07-03

Staff is very friendly. You can tell that Dr. Kim Wolf and staff cares about their patients and will do their best to assist you. Came in because I had a lingering cough. After a two week follow up, it was very easy for me to get a referral to a lung specialist.

Blake P.★★★★★2026-06-30

First visit to Little Elm Medial Clinic today 6/30. Entire staff is incredibly friendly and professional. When I need them I will definitely call them. - Blake Porter

Renee B.★★★★★2026-06-25

Kim is kind and caring. She really takes the time to help you. I highly recommend!

Sheri P.★★★★★2026-06-24

Wonderful, caring practice that listens to your concerns.

Analysis by RetaMaps of reviews on this practice's public Google Business listing; review themes are detected automatically and reviews reflect their authors' opinions. See all reviews on Google.

Nearby providers in Little Elm

Retatrutide status
Phase 3 complete · Not FDA-approvedUpdated October 2, 2026

Retatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors). Five Phase 3 trials have reported positive results, and Lilly plans to submit it to the FDA in Q1 2027. It is not FDA-approved, has no brand name or price, and cannot be prescribed outside clinical trials or Lilly's physician-requested expanded access program. Products sold online as "research" or compounded retatrutide are not legitimate retatrutide.

Development
Phase 3 complete
FDA status
Submission planned — Q1 2027 (Lilly guidance)
Availability
Not commercially available
Access routes
Clinical trials, or Lilly's expanded access program (physician must apply)

Next milestone: TRIUMPH-5 head-to-head vs tirzepatide results (Expected ~Dec 2026)

Sources: Lilly — What to know about retatrutide · Lilly — TRIUMPH-2/TRIUMPH-3 results · BioPharma Dive — FDA submission plans · STAT — Lilly expanded access (Aug 3, 2026) · FDA — Concerns with unapproved GLP-1 drugs